Enanta sues Pfizer for patent infringement over Paxlovid, seeks damages only

ENANTA PHARMACEUTICALS INC

Filed suit against Pfizer in U.S. District Court for Massachusetts over U.S. Patent No. 11,358,953 covering coronavirus protease inhibitors.
Patent was awarded earlier in June 2022 based on a July 2020 application; Enanta claims Pfizer's Paxlovid infringes.
Enanta states it will not seek an injunction or take action to block production, sale, or distribution of Paxlovid.
Enanta seeks 'fair compensation' for Pfizer's use of the coronavirus protease inhibitor claimed in the '953 patent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.